Efficacy [qlco]    
Patients [podg]    
HEPATITIS B VIRUS [virs]    
Related [qlco]    
Compensated [qlco]    
CIRRHOSIS [dsyn]    
Limited [ftcn]    
Efficacy [qlco]    
LDT [moft]    
therapy [ftcn]    
Patients [podg]    
Hepatitis B, Chronic [dsyn]    
Compensated [qlco]    
CIRRHOSIS [dsyn]    
Evaluated [hlca]    
LDT [moft]    
First-Line Therapy [topp]    
Patients [podg]    
Compared [acty]    
Treated [ftcn]    
Hepatitis B, Chronic [dsyn]    
Patients [podg]    
Compensated [qlco]    
CIRRHOSIS [dsyn]    
Treated [ftcn]    
LDT [moft]    
> 2 years [fndg]    
Less [qnco]    
> 2 years [fndg]    
Resistance [menp]    
Evaluated [hlca]    
Efficacy [qlco]    
matched [resa]    
Control Group [grup]    
Treated [ftcn]    
Comparison [acty]    
LDT [moft]    
Group [idcn]    
Normalization [resa]    
HEPATITIS B E ANTIGEN [imft]    
Seroconversion [npop]    
Virologic [ftcn]    
Resistance [menp]    
Note [clna]    
> 2 years [fndg]    
treatment [ftcn]    
Compared [acty]    
Group [idcn]    
Virologic [ftcn]    
Resistance [menp]    
Addition [ftcn]    
SERUM [bdsu]    
Hepatitis B surface antigen level [lbpr]    
HEPATOCELLULAR CARCINOMA [neop]    
Mortality [qnco]    
Disease Progression [patf]    
Renal function [ortf]    
Regression Analysis [inpr]    
Pretreatment [sbst]    
low albumin [fndg]    
Model for end-stage liver disease score [clna]    
Risk Factors [qnco]    
Disease Progression [patf]    
Indicated [fndg]    
LDT [moft]    
Patients [podg]    
HEPATITIS B VIRUS [virs]    
Related [qlco]    
Compensated [qlco]    
CIRRHOSIS [dsyn]    
LDT [moft]    
LOWER [spco]    
HEPATITIS B VIRUS [virs]    
Higher [qlco]    
Resistant [ftcn]    
> 2 years [fndg]    
treatment [ftcn]    
Challenge [clna]    
First-Line Therapy [topp]    
Patients [podg]    
Need [qlco]    
therapy [ftcn]    
